COO Cooper Companies (The)

Q1 2025 10-Q

Filed: Mar 7, 2025Period ending Jan 31, 2025

Health Care

Ophthalmic GoodsSEC EDGAR

Cooper Companies (The) (COO) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Mar 7, 2025 for the fiscal period ending Jan 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• No new or materially changed risk factors reported since 2024 10-K filing
• Regulatory risk focused on FDA and NMPA approvals for MiSight 1 day myopia management lens in US and China

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$965M

Net Income

$104M

Gross Margin

68.4%

Operating Margin

18.9%

Net Margin

10.8%

ROE

1.3%

Total Assets

$12.4B

Source: XBRL data from Cooper Companies (The) Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Cooper Companies (The) Quarterly Reports

Q1 2026 10-Q

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Cooper Companies (The)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.